Pharmaceutical Processing

Rapid-acting insulin specialist MannKind Corp. (NSDQ:MNKD) has enrolled the first pediatric patient in its INHALE-1 study evaluating its Afrezza (Technosphere Insulin) with basal insulin versus multiple daily injections of insulin. The study will enroll participants aged four to 17 with type 1 or type 2 diabetes. Afrezza first won FDA approval in 2014, and MannKind…

Honeywell (NASDAQ:HON) will integrate manufacturing execution system (MES) software offerings from Performix Inc. into its portfolio of offerings for life science companies. Financial details of the transaction were not disclosed. Houston, Texas–based Performix specializes in creating MES software for pharma and biotech companies. The company also has an office in Pune, India. Late last year, Honeywell…

Starting January 1, 2021, Eli Lilly and Company (NYSE:LLY) will reduce the list price of Insulin Lispro Injection in the U.S. to match 2008 levels. The 40% price cut will also extend to the company’s non-branded insulins. Still, the company acknowledged that people with fixed insurance co-pays or beneficiaries of Lilly’s affordability programs might not…

A former information technology (IT) executive at Mylan today pleaded guilty to conspiracy to commit securities fraud and aiding in the preparation of a false tax return. Dayakar Mallu, who at the time of the fraud served as VP of global operations information technology at Mylan, admitted to the charges in court in the Western…

The Biden administration reportedly plans to purchase and share with the world hundreds of millions of doses of Pfizer’s COVID-19 vaccine. The Washington Post reported today that the U.S. has plans to make another large purchase of COVID-19 vaccines, although details of the deal have not been made clear. Neither the White House nor Pfizer…

Catalent announced today that it entered into a commercial supply agreement with Phathom Pharmaceuticals for its acid blocker. The commercial supply agreement covers Phathom’s lead compound, vonoprazan, which is a novel, orally active-potassium competitive acid blocker (P-CAB) for treating gastrointestinal diseases, according to a news release. Phathom currently has vonoprazan in late clinical-stage development for…

Cardinal Health’s board of directors reduced bonus payouts for CEO Mike Kaufmann and his four top-paid executives due to the cost of opioid litigation. After pressure from investors, Cardinal Health (NYSE:CAH) for the first time has disclosed how its board of directors factored the opioid litigation settlement costs into the pay packages of Kaufmann, Chief…

Bausch Health (NYSE/TSX:BHC), formerly known as Valeant Pharmaceuticals, has agreed to pay $300 million to settle allegations that the company paid rivals to keep a generic version of Glumetza off the market. In 2015, the Laval, Canada–based company increased the drug’s price by almost eight-fold. The plaintiffs, drug distributor companies, in the class-action suit filed…

Eli Lilly and Company (NYSE: LLY) has announced its plan to issue €600 million in aggregate principal in the amount of 0.50% notes with 12-year maturity as part of its Environmental, Social and Governance (ESG) strategy. In May, the company announced that it had updated its Environmental, Social and Governance (ESG) strategy, bolstering its investment…

While mRNA vaccines from Moderna (NSDQ:MRNA) and Pfizer (NYSE:PFE) had 95% efficacy in Phase 3 clinical trials, their effectiveness in the real world has dropped with the rise of the Delta variant.  As a result, breakthrough infections have grown more common in people who have received two doses of mRNA vaccines. Ultimately, full vaccination may require…